^
    22d
    Pattern of Somatic Mutations in the PIK3CA Oncogene and Their Role as a Potential Prognostic Biomarker in Breast Cancer Patients in Sri Lanka: A Pilot Study. (PubMed, Asian Pac J Cancer Prev)
    Despite being a pilot study, the findings indicate that PIK3CA mutations are associated with adverse prognostic outcomes in Sri Lankan breast cancer patients. These results demonstrate the potential utility of PIK3CA testing and PI3K-targeted therapy in clinical management in Sri Lankan, pending validation in larger cohorts.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    PIK3CA mutation
    |
    QClamp® PIK3CA Mutation Detection Test
    over3years
    The ColoScape Test: A Novel QClamp XNA TechnologyBased Assay to Detect Colorectal Cancer Associated Mutations and Methylations in Plasma Cell-Free DNA (AMP 2022)
    The ColoScape test utilizing the XNA-based technology provides high sensitivity and high specificity to CRC and advanced adenomas with a great potential to be used as an early screening test.
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SMAD4 (SMAD family member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway)
    |
    TP53 mutation • KRAS mutation • BRAF mutation • PIK3CA mutation
    |
    ColoScape™ Colorectal Cancer Mutation Detection Test • QClamp® BRAF Mutation Detection Test • QClamp® KRAS Mutation Detection Test • QClamp® NRAS Mutation Detection Kit • QClamp® PIK3CA Mutation Detection Test